Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from CSL ( (AU:CSL) ).
CSL Limited announced a change in the director’s interest, specifically involving Ms. Alison Watkins AM, who has acquired 154 Ordinary Shares through the exercise of rights under the CSL Limited Non-Executive Director Rights Plan. This transaction reflects the company’s ongoing commitment to aligning director interests with shareholder value, as directors contribute a portion of their board fees to acquire equity, potentially impacting CSL’s governance and stakeholder confidence positively.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$282.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and delivery of innovative medicines and vaccines. The company is known for its research and production of therapies for rare and serious diseases, with a strong market presence globally.
Average Trading Volume: 962,418
Technical Sentiment Signal: Sell
Current Market Cap: A$104.8B
For a thorough assessment of CSL stock, go to TipRanks’ Stock Analysis page.